Related Experiment Videos
Low molecular weight heparins and coronary artery disease
1CSU Pharmaceutical Sciences, Vancouver Hospital and Health Sciences Center, BC, Canada. zed@interchange.ubc.ca.
Insights
Low molecular weight heparins (LMWHs) are more effective than unfractionated heparin (UFH) for acute coronary syndromes. LMWHs offer improved outcomes and cost-effectiveness with similar major bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) includes conditions like unstable angina and myocardial infarction.
- Acute coronary syndromes (ACS) result from atherosclerotic plaque rupture and thrombosis.
- Unfractionated heparin (UFH) is a traditional treatment for ACS.
Purpose of the Study:
- To compare the efficacy and safety of low molecular weight heparins (LMWHs) versus UFH in managing ACS.
- To evaluate the cost-effectiveness of LMWH compared to UFH.
Main Methods:
- Systematic review of available evidence comparing LMWH and UFH in ACS patients.
- Analysis of clinical outcomes, including ischemic events, death, and bleeding complications.
- Assessment of cost-effectiveness.
Main Results:
- LMWH demonstrated superiority over UFH in reducing ischemic events or death during the acute phase of unstable angina or non-Q-wave myocardial infarction.
- Major bleeding complication rates were similar between LMWH and UFH.
- Minor bleeding complications, primarily injection-site hematomas, were more frequent with LMWH.
- LMWH use was found to be cost-effective compared to UFH.
Conclusions:
- LMWH offers improved clinical outcomes and a favorable safety profile compared to UFH for unstable angina and non-Q-wave myocardial infarction.
- LMWH is a cost-effective treatment option and should be favored over UFH in these patient populations.
- Long-term LMWH therapy at lower doses did not show advantages over aspirin for preventing coronary events.
Abstract:
Coronary artery disease encompasses a wide spectrum of conditions including silent ischemia, exertional angina, unstable angina, and myocardial infarction. Acute coronary syndromes (unstable angina and myocardial infarction) are caused by the rupture of an atherosclerotic plaque, platelet activation, and fibrin deposition resulting in thrombosis. Aspirin and unfractionated heparin (UFH) have traditionally been the treatment of choice in patients with acute coronary syndromes; however, low molecular weight heparins (LMWHs) offer potential advantages over UFH. Available evidence indicates that LMWH is superior to UFH in reducing ischemic events or death in the acute phase of unstable angina or non-Q-wave myocardial infarction. Long-term therapy with lower doses of LMWH may not offer any advantage to aspirin in the prevention of coronary events or death. Major bleeding complications are similar for LMWH and UFH although minor bleeding complications are more common with LMWH, primarily due to injection-site hematomas. Finally, use of LMWH appears to be cost- effective compared with UFH. The available evidence supports improved clinical outcomes, favorable safety profile, and cost savings associated with LMWH use in the management of unstable angina and non-Q-wave myocardial infarction and should be favored over UFH.